Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Neurotrope, Inc is a biotechnology business based in the US. Neurotrope shares (NTRP) are listed on the NASDAQ and all prices are listed in US Dollars. Neurotrope employs 5 staff and has a market cap (total outstanding shares value) of USD$22.4 million.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Mobile users
Latest market close | USD$0.941 |
---|---|
52-week range | USD$0.6808 - USD$1.55 |
50-day moving average | USD$1.0323 |
200-day moving average | USD$1.1513 |
Wall St. target price | USD$1 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.477 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.941 from 2020-12-02
1 week (2021-01-13) | N/A |
---|---|
1 month (2020-12-20) | N/A |
3 months (2020-10-20) | N/A |
6 months (2020-07-20) | N/A |
1 year (2020-01-20) | N/A |
---|---|
2 years (2019-01-20) | N/A |
3 years (2018-01-20) | N/A |
5 years (2016-01-20) | N/A |
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -27.73% |
Return on equity TTM | -52.59% |
Profit margin | 0% |
Book value | $1.171 |
Market capitalisation | USD$22.4 million |
TTM: trailing 12 months
There are currently 46,336 Neurotrope shares held short by investors – that's known as Neurotrope's "short interest". This figure is 75.5% down from 189,206 last month.
There are a few different ways that this level of interest in shorting Neurotrope shares can be evaluated.
Neurotrope's "short interest ratio" (SIR) is the quantity of Neurotrope shares currently shorted divided by the average quantity of Neurotrope shares traded daily (recently around 243873.68421053). Neurotrope's SIR currently stands at 0.19. In other words for every 100,000 Neurotrope shares traded daily on the market, roughly 190 shares are currently held short.
However Neurotrope's short interest can also be evaluated against the total number of Neurotrope shares, or, against the total number of tradable Neurotrope shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neurotrope's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Neurotrope shares in existence, roughly 0 shares are currently held short) or 0.002% of the tradable shares (for every 100,000 tradable Neurotrope shares, roughly 2 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Neurotrope.
Find out more about how you can short Neurotrope stock.
We're not expecting Neurotrope to pay a dividend over the next 12 months.
Neurotrope's shares were split on a 1:32 basis on 12 January 2017. So if you had owned 32 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Neurotrope shares – just the quantity. However, indirectly, the new 3100% higher share price could have impacted the market appetite for Neurotrope shares which in turn could have impacted Neurotrope's share price.
Over the last 12 months, Neurotrope's shares have ranged in value from as little as $0.6808 up to $1.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurotrope's is 2.2587. This would suggest that Neurotrope's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.